Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision
TSANZ · 2024 · Australia
Source and licence
- Authors
- John A. Mackintosh, Gregory Keir, Lauren K. Troy et al.
- Title
- Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision
- Journal
- Respirology (Carlton, Vic.), 2024
- Licence
- CC BY 4.0
- Changes
- Verbatim excerpts; formatting adapted
Full text retrieved 2026-10-27 from Europe PMC · PMC10952210
Licence statement of the original publication
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.
Open the original publication →Full text on Europe PMC
Recommendations
We found no explicitly labelled recommendations in this publication; its recommendations are in the running text of the original.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti‐fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non‐IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non‐pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi‐faceted approach to the management of IPF and progressive pulmonary fibrosis.
Contents of the original publication
The section headings of the original.
- INTRODUCTION
- METHODS
- PHARMACOLOGICAL THERAPY
- Anti‐fibrotic therapy
- Anti‐reflux therapy
- Progressive pulmonary fibrosis
- Clinical trials for IPF and PPF
- Acute exacerbations of IPF
- Treatment and impact of co‐morbidities
- NON‐PHARMACOLOGICAL THERAPY
- Oxygen therapy
- Pulmonary rehabilitation
- General health measures and patient self‐management
- Vaccination
- COVID‐19
- ILD specialist nurses
- Lung transplantation
- Symptom management and palliative care
- Psychosocial/family support
- PRECISION MEDICINE AND GENETICS
- CONCLUSIONS AND FUTURE CONSIDERATIONS
A question about this guideline?
Medelix answers clinical questions from guidelines and studies – every statement with its source.
Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint